期刊文献+

Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients

Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients
下载PDF
导出
摘要 The combination of hepatitis B immune globulin with entecavir or tenofovir(at least for a certain period of time) seems to be the most reasonable prophylaxis against recurrent hepatitis B after liver transplantation. Entecavir represents an attractive option for treatment of na?ve kidney transplant recipients, because of its high efficacy and the low rates of resistance. However antiviral treatment should be individualized in the view of kidney function and the previous resistance. To date, new captivating therapeutic strategies could make interferon-free regimens viable for treatment of hepatitis C virus positive liver transplant recipients. The recent combinations of sofosbuvir with simeprevir or daclatasvir or ledipasvir plus/minus ribavirin have boosted the on treatment and sustained virological response to rates approaching 100% within liver transplant recipients with recurrent chronic hepatitis C(CHC). Preliminary data showed that the second generation direct oral antivirals could result to high treatment rates of recurrent CHC in kidney transplant recipients as well. Ongoing studies will clarify the optimal treatment of recurrent CHC in kidney transplant recipients. The combination of hepatitis B immune globulin with entecavir or tenofovir(at least for a certain period of time) seems to be the most reasonable prophylaxis against recurrent hepatitis B after liver transplantation. Entecavir represents an attractive option for treatment of na?ve kidney transplant recipients, because of its high efficacy and the low rates of resistance. However antiviral treatment should be individualized in the view of kidney function and the previous resistance. To date, new captivating therapeutic strategies could make interferon-free regimens viable for treatment of hepatitis C virus positive liver transplant recipients. The recent combinations of sofosbuvir with simeprevir or daclatasvir or ledipasvir plus/minus ribavirin have boosted the on treatment and sustained virological response to rates approaching 100% within liver transplant recipients with recurrent chronic hepatitis C(CHC). Preliminary data showed that the second generation direct oral antivirals could result to high treatment rates of recurrent CHC in kidney transplant recipients as well. Ongoing studies will clarify the optimal treatment of recurrent CHC in kidney transplant recipients.
机构地区 Division of Nephrology [
出处 《World Journal of Gastrointestinal Pharmacology and Therapeutics》 CAS 2015年第4期105-110,共6页 世界胃肠药理与治疗学杂志(英文版)(电子版)
关键词 VIRAL HEPATITIS HEPATITIS C RECURRENCE HEPATITIS B Viral hepatitis Hepatitis C recurrence Hepatitis B
  • 相关文献

参考文献20

  • 1M. Mandorfer,K. Kozbial,C. Freissmuth,P. Schwabl,A. F. St?ttermayer,T. Reiberger,S. Beinhardt,R. Schwarzer,M. Trauner,A. Ferlitsch,H. Hofer,M. Peck‐Radosavljevic,P. Ferenci.Interferon‐free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses[J]. Aliment Pharmacol Ther . 2015 (6)
  • 2E. Cholongitas,T. Vasiliadis,I. Goulis,I. Fouzas,N. Antoniadis,V. Papanikolaou,E. Akriviadis.Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease[J]. J Viral Hepat . 2015 (7)
  • 3Maria Francesca Donato,Sara Monico,Federica Malinverno,Alessio Aghemo,Marco Maggioni,Paolo Reggiani,Massimo Colombo.Bridging all oral DAA therapy from wait time to post‐liver transplant to improve HCV eradication?[J]. Liver Int . 2015 (1)
  • 4Michael P. Curry,Xavier Forns,Raymond T. Chung,Norah A. Terrault,Robert Brown,Jonathan M. Fenkel,Fredric Gordon,Jacqueline O’Leary,Alexander Kuo,Thomas Schiano,Gregory Everson,Eugene Schiff,Alex Befeler,Edward Gane,Sammy Saab,John G. McHutchison,G. Mani Subramanian,William T. Symonds,Jill Denning,Lindsay McNair,Sarah Arterburn,Evguenia Svarovskaia,Dilip Moonka,Nezam Afdhal.Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study[J]. Gastroenterology . 2014
  • 5A. Perrella,A.G. Lanza,D. Pisaniello,G. DiCostanzo,F. Calise,O. Cuomo.Telbivudine Prophylaxis for Hepatitis B Virus Recurrence After Liver Transplantation Improves Renal Function[J]. Transplantation Proceedings . 2014 (7)
  • 6Roche, Bruno,Samuel, Didier.Prevention of Hepatitis B Virus Reinfection in Liver Transplant Recipients[J]. Intervirology . 2014 (3-4)
  • 7E. J. Gane,K. Agarwal.Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: “A Flood of Opportunity”[J]. American Journal of Transplantation . 2014 (5)
  • 8J.‐H. Cho,J.‐H. Lim,G.‐Y. Park,J.‐S. Kim,Y.‐J. Kang,O. Kwon,J.‐Y. Choi,S.‐H. Park,Y.‐L. Kim,H.‐K. Kim,S. Huh,C.‐D. Kim.Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection[J]. Transpl Infect Dis . 2014 (2)
  • 9C. Pipili,E. Cholongitas,G. Papatheodoridis.Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease[J]. Aliment Pharmacol Ther . 2014 (1)
  • 10E. Cholongitas,G.V. Papatheodoridis.High Genetic Barrier Nucleos(t)ide Analogue(s) for Prophylaxis From Hepatitis B Virus Recurrence After Liver Transplantation: A Systematic Review[J]. American Journal of Transplantation . 2012 (2)

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部